Clinofibrate decreased FLT-FRET between FMAL-actin and TMR-cC0-C2 relative to the DMSO control. In KYSE450 cells, Clinofibrate was identified as a potent suppressor of SNORA80B, with expression measured by qPCR and normalized by U6. [1,2]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Clinofibrate Effects on FLT-FRET
Cell-based study · FMAL-actin and TMR-cC0-C2 [1]
In the FMAL-actin and TMR-cC0-C2 model, Clinofibrate decreased FLT-FRET between FMAL-actin and TMR-cC0-C2 relative to the DMSO control.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.5–100 μM
- Vehicle
- DMSO
- Reported limits
- Not stated in the sentences used: route, schedule.
Methods and source locations
Compound reported in the paper: Clinofibrate
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Experimental procedures > Concentration–response assay (S128, S129, S130); Figure 5 legend (S187, S189)
normalized FRET efficiency (E/EDMSO): normalized FRET efficiency (E/EDMSO); comparator: DMSO — Figure 5 legend (S187, S189)
Clinofibrate Suppression of SNORA80B in KYSE450 Cells
Cell-based study · KYSE450 cells [2]
Clinofibrate was administered to KYSE450 cells, and SNORA80B expression was measured by qPCR and normalized by U6, with parental cells as the control. Clinofibrate was identified as a potent suppressor of SNORA80B.
Literature-Reported Treatment Conditions
- Exposure duration
- Following 24 h adherence, individual FDA‐approved drugs from the screening library (Selleckchem, Cat. #L1300) were administered to cells for 48 h.
- Method
- administered to cells
- Reported limits
- Not stated in the sentences used: dose, vehicle.
Methods and source locations
Compound reported in the paper: Clinofibrate
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Screening of Clinofibrate as a Potent Inhibitor of SNORA80B (S96); Experimental Section > High Throughput Screening for SNORA80B Inhibitor (S197, S198, S200, S201)
The expression of SNORA80B was measured by qPCR and normalized by U6.: The expression of SNORA80B was measured by qPCR and normalized by U6.; comparator: parental cells — Results > Screening of Clinofibrate as a Potent Inhibitor of SNORA80B (S96); Experimental Section > High Throughput Screening for SNORA80B Inhibitor (S200)